GENERAL16 Sept 2026
Domestic pharma market sustains growth momentum, but margins remain key
India's pharma market grew 13% in August to ₹24,800 crore, helped by price hikes and new launches, though volumes rose just 0.6%. Chronic therapies grew faster than acute ones. This matters for pharma companies and their investors, because US tariff uncertainty on generic drugs can still squeeze margins. Watch September-quarter margins and your US business exposure closely.
Key Statutory Highlights
- Pharma market revenue grew 13% year-on-year in August to ₹24,800 crore, a little lower than July's 14% growth.
- Growth came mainly from price hikes and new launches, since volumes increased by only 0.6%.
- The US has said imported generic drugs will face a 100% tariff from August 2028 and 200% from August 2029.
Actionable Advice for Taxpayers / Founders:If you deal in pharma stocks or run a pharma business, review how much of your earnings depends on US generic exports, and keep an eye on the September-quarter margin numbers before taking any fresh call.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: